Chemotherapy Consisting of Cisplatin, Epirubicin, and Cyclophosphamide in Advanced Ovarian Carcinoma
Author:
Publisher
Informa UK Limited
Subject
Cancer Research,Oncology,General Medicine
Link
http://www.tandfonline.com/doi/pdf/10.3109/07357909309020253
Reference8 articles.
1. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. Italian Multicentre Breast Study with Epirubicin.
2. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.
3. Randomised trial comparing combinations of cyclophosphamide and cisplatin without or with doxorubicin or 4′-epi-doxorubicin in the treatment of advanced ovarian cancer
4. Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma.
5. Long-Term Follow-Up of Patients with Advanced Ovarian Carcinoma Treated with Debulking Surgery and Chemotherapy Consisting of Cisplatin, Doxorubicin, and Cyclophosphamide
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis;Journal of Clinical Oncology;2023-09-01
2. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis;J CLIN ONCOL;2002
3. Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis;Journal of Clinical Oncology;2002-03-01
4. Cyclophosphamide, epirubicin and cisplatin (CEP) versus epirubicin plus cisplatin (EP) in stage Ic-IV ovarian cancer: a randomized phase III trial of the Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg;Anti-Cancer Drugs;1999-03
5. The role of anthracyclines in epithelial ovarian cancer;Annals of Oncology;1999
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3